Want to invest in a new profitable growing industry?
FSD Pharma with the acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (“Lucid”). If there was ever a right moment to invest in a growing industry, that time is now! Lucid is a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases. The mental health industry is a multi billion dollar industry and FSD along with Lucid are making the right moves to be part of the future, will you?
FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History
- Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models.
- Strategically advancing drug candidate pipelines focused on novel and unique therapies for neurodegenerative and psychiatric disorders.
- Well-capitalized to pursue acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on Total Brain Health.
- Unique CAP structure with over 150,000 shareholders as of July 29, 2021.
- Balance sheet is free of debt and has over US $43.2M in cash as of June 30, 2021.